Low‐pressure insufflation with warmed and humidified CO 2 versus cold and dry CO 2 in laparoscopic colorectal surgery: Protocol for the PAROS 3 randomized controlled trial
Colorectal Disease · 2026-11 · 28 (11)
DOI: 10.1111/codi.70683 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Colorectal Disease, online erschienen am 16.11.2026. Verfasst von Quentin Denost und 6 weiteren Autor:innen. Beteiligte Einrichtung: Bordeaux Colorectal Institute, Tivoli Clinic, Bordeaux, France. Hauptthemen laut MEDLINE: Carbon Dioxide, Insufflation, Laparoscopy, Pneumoperitoneum, Artificial. Die Arbeit nennt 28 Literaturangaben.
Abstract (Originalsprache)
Background
Low‐pressure pneumoperitoneum (LPP) has been shown to reduce postoperative pain and analgesic requirements after laparoscopic colorectal surgery. In parallel, warm and humidified carbon dioxide (WHCO 2 ) insufflation provides a more physiological peritoneal environment and may further improve postoperative recovery. However, the combined effect of LPP and WHCO 2 has not been specifically evaluated in colorectal surgery.
Aim
To determine whether the addition of WHCO 2 to LPP further reduces postoperative pain and opioid consumption compared with LPP alone in patients undergoing laparoscopic colorectal resection.
Methods
PAROS3 is a French prospective, bicentric, randomized, controlled superiority trial. Adult patients scheduled for elective laparoscopic or robot‐assisted colorectal resection under LPP (5–8 mmHg) will be randomized (1:1) to receive either WHCO 2 insufflation (experimental group) or standard cold and dry CO 2 (control group). The study is double‐blinded for patients and evaluators of the primary endpoint, and open‐label for the “operator” surgeon. The primary endpoint is the proportion of patients with a visual analogue scale (VAS) pain score ≤3 at 24 h after surgery, without consumption of level II or III analgesics. Secondary endpoints include operating time, conversion rates, perioperative haemodynamic and temperature variations, inflammatory markers, postoperative complications, oncological quality, length of stay, analgesic consumption up to 30 days, and quality of life at 3 months. Analysis will be performed on an intention‐to‐treat basis. A total of 148 patients are planned for inclusion. Trial Status Recruitment is ongoing. Protocol version 3.1, August 25, 2025. Registration ClinicalTrials.gov: NCT05934981.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bordeaux Colorectal Institute, Tivoli Clinic, Bordeaux, France.
- Department of Digestive Surgery, Aix-Marseille University, APHM, Hôpital Nord, Marseille, France.
- Department of Anesthesiology, Tivoli Clinic, Bordeaux, France.
- Department of Anesthesiology and Intensive Care, Hospital Nord, APHM, Aix Marseille Université, Marseille, France.
ORCID-Profile: Quentin Denost, Laura Beyer-Berjot, Barbara Noiret
Zitieren
APA
Denost, Q., Beyer-Berjot, L., Soubirou, J. F., De Cazes, Y., Pastene, B., Blanc, M. C., & Noiret, B. (2026). Low‐pressure insufflation with warmed and humidified CO 2 versus cold and dry CO 2 in laparoscopic colorectal surgery: Protocol for the PAROS 3 randomized controlled trial. Colorectal Disease, 28(11). https://doi.org/10.1111/codi.70683
Vancouver
Denost Q, Beyer-Berjot L, Soubirou JF, De Cazes Y, Pastene B, Blanc MC, et al. Low‐pressure insufflation with warmed and humidified CO 2 versus cold and dry CO 2 in laparoscopic colorectal surgery: Protocol for the PAROS 3 randomized controlled trial. Colorectal Disease. 2026;28(11). doi:10.1111/codi.70683
BibTeX
@article{Denost2026,
author = {Denost, Quentin and Beyer-Berjot, Laura and Soubirou, Jean-François and De Cazes, Yannick and Pastene, Bruno and Blanc, Marie-Caroline and Noiret, Barbara},
title = {Low‐pressure insufflation with warmed and humidified CO 2 versus cold and dry CO 2 in laparoscopic colorectal surgery: Protocol for the PAROS 3 randomized controlled trial},
journal = {Colorectal Disease},
year = {2026},
volume = {28},
number = {11},
doi = {10.1111/codi.70683}
}
EUVIMED